Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

58.87 +0.64 (+1.10%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
66 67 Next >
Is Bristol Myers' Dividend in Danger?
Should investors brace for a dividend cut? 
Via The Motley Fool
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
From Bristol Myers Squibb
Via Business Wire
Bounce Alert: 3 Large Caps With RSIs Too Good To Ignore
The sudden divergence has made clear some laggards who have ultra-low RSI readings that might just be too good to ignore. Here are 3 worth watching closely. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
What's Going On With Medical Therapeutic Firm Aethlon Medical On Friday?
Aethlon Medical unveils results in removing extracellular vesicles (EVs) from plasma. Preclinical evidence supports upcoming phase 1 trials for solid tumor patients undergoing anti-PD-1 monotherapy. 
Via Benzinga
2 Beaten-Down Stocks to Buy and Hold for 10 Years
They offer plenty of upside and solid dividend growth. 
Via The Motley Fool
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 5% Dividend Yields
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
Investing in high-yield dividend stocks under $50 is a low-risk strategy that can result in massive returns in time. 
Via InvestorPlace
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
From Bristol Myers Squibb
Via Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
From Bristol Myers Squibb
Via Business Wire
Uncover the Potential: 3 Discounted Stocks Ready for a Comeback
Investors should considered these discounted stocks to buy for generous returns due to current undervaluation and strong fundamentals. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
Keep your goals in check when considering an extreme contrarian trade with Bristol Myers Squibb stock. 
Via The Motley Fool
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
The answer isn't great, but there's still reason to like Bristol Myers Squibb. 
Via The Motley Fool
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases 
From Editas Medicine, Inc.
Via GlobeNewswire
3 Top ETFs to Buy for Passive Income in May
These ETFs provide investors with above-average income streams. 
Via The Motley Fool
Topics ETFs
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
10 worst performing large-cap stocks last week: LKQ, MSCI, TXT, EDU, BMY, MANH, RS, META, LUV, NUE. Analysts cut price targets for many. 
Via Benzinga
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
Via Benzinga
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Microsoft, Tesla, Google, GE and Chipotle were earnings winners. Meta was a notable loser. 
Via Investor's Business Daily
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.